CDK1 and non-small cell lung carcinoma: This might be the reason why p-Y15/T14 CDK1 was more positively associated drug sensitivity than total CDK1 in the COMPARE analysis, and why cytoplasmic CDK1 loss confers chemotherapeutic resistance and worse survival in NSCLC patients.